Candel Therapeutics
(NASDAQ) CADL
Candel Therapeutics Financials at a Glance
Market Cap
$721.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$54.42M
EPS (TTM)
-$0.98
P/E Ratio
-10.07
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$9.87
Volume
1,945,023
Open
$9.63
Price
$9.87
Volume
1,945,023
Open
$9.63
Previous Close
$9.88
Daily Range
$9.49 - $9.95
52-Week Range
$4.35 - $11.36
Estimated Earnings Date
Aug 13, 2026
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$9.87
Volume
1,945,023
Open
$9.63
Previous Close
$9.88
Daily Range
$9.49 - $9.95
52-Week Range
$4.35 - $11.36
Estimated Earnings Date
Aug 13, 2026
CADL News
CADL: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Candel Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
55
CEO
Paul-Peter Tak, MD, PhD
Website
www.candeltx.comHeadquarters
Needham, MA 02494, US
CADL Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-60.42%
Return on Capital
-89.67%
Return on Assets
-26.95%
Earnings Yield
-9.93%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$721.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
73.27M
Volume
1.95M
Avg. Volume
2.09M
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$56.42M
EBITDA
-$50.30M
Operating Cash Flow
-$47.73M
Capital Expenditure
-$1.26M
Free Cash Flow
-$48.99M
Cash & ST Invst.
$194.83M
Total Debt
$1.80M
Candel Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$721.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$13.12M
N/A
Employees
55
N/A
Net Income
-$8.86M
-220.1%
EBITDA
-$7.15M
-190.1%
Quarterly Fundamentals
Total Cash
$194.83M
+111.4%
Total Debt
$1.80M
-83.5%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$1.34M
+15.7%
Short Term Debt
$453.00K
-95.4%
Return on Assets
-26.95%
N/A
Return on Invested Capital
-28.95%
N/A
Free Cash Flow
-$18.71M
-117.1%
Operating Cash Flow
-$18.04M
-109.3%